New Markers of Inflammation and Endothelial Cell Activation
Paul E. Szmitko(St. Michael's Hospital), Subodh Verma(St. Michael's Hospital)
Cited by 733
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693
Endothelial cell control of thrombosis
|BMC Cardiovascular Disorders|2015|678